IKE (Imidazole ketone erastin )
产品说明书
 |
同义名 : | Imidazole Ketone Erastin;PUN30119;IKE |
| CAS号 : | 1801530-11-9 | |
| 货号 : | A1155014 | |
| 分子式 : | C35H35ClN6O5 | |
| 纯度 : | 99%+ | |
| 分子量 : | 655.143 | |
| MDL号 : | MFCD31813799 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(160.27 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Ferroptosis is a form of regulated cell death that can be induced by inhibition of the cystine-glutamate antiporter, system xc-. Among the existing system xc- inhibitors, imidazole ketone erastin (IKE) is a potent, metabolically stable inhibitor of system xc- and inducer of ferroptosis potentially suitable for in vivo applications[1]. The IC50 of GSH depletion by IKE was 34 nM in SUDHL6 cells. Analysis of lipid reactive oxygen species (ROS) by flow cytometry using the lipid peroxidation probe C11-BODIPY revealed a dose-dependent increase in lipid ROS upon IKE treatment in SUDHL6 cells. Immunofluorescence staining with an anti-dihydropyridine-MDA-lysine adduct antibody (mAb 1F83) revealed that dihydropyridine-MDA-lysine adduct abundance was increased upon IKE treatment[1]. The system xc- component SLC7A11, prostaglandin-endoperoxide synthase 2 (PTGS2, which encodes cyclooxygenase-2), and ChaC GSH-specific γ-glutamylcyclotransferase 1 (CHAC1) expression was significantly increased in SUDHL6 cells following IKE treatment[1]. IKE exhibits antitumor activity in DLBCL (diffuse large B cell lymphoma) xenograft model, which correlates with an increase of lipid peroxidation in tumors. These findings suggest that IKE can be effective as a potential therapeutic regimen for DLBCL[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.53mL 0.31mL 0.15mL |
7.63mL 1.53mL 0.76mL |
15.26mL 3.05mL 1.53mL |
| 参考文献 |
|---|